Bhambri, Rahul
Colavecchia, A. Carmine
Bruno, Marianna
Chen, Yong
Alvir, Jose
Roy, Anuja
Kemner, Jason
Crowley, Aaron
Benjumea, Darrin
Gilstrap, Lauren
Clinical trials referenced in this document:
Documents that mention this clinical trial
Real-World Characteristics of Patients with Wild-Type Transthyretin Amyloid Cardiomyopathy: An Analysis of Electronic Healthcare Records in the United States
https://doi.org/10.1007/s40256-022-00563-4
Tafamidis and Quality of Life in People With Transthyretin Amyloid Cardiomyopathy in the Study ATTR-ACT: A Plain Language Summary
https://doi.org/10.2217/fca-2021-0095
Personalized medicine approach for optimizing the dose of tafamidis to potentially ameliorate wild-type transthyretin amyloidosis (cardiomyopathy)
https://doi.org/10.3109/13506129.2015.1063485
Towards improving clinical and patient-centred outcomes in patients with light chain amyloidosis
https://doi.org/10.1136/heartjnl-2022-321139
Funding for this research was provided by:
Pfizer
Article History
Accepted: 14 December 2022
First Online: 13 February 2023
Declarations
:
: This study was sponsored by Pfizer.
: Pfizer contributed to the study design and management and collection of data. In their role as authors, employees of Pfizer were involved in the interpretation of data; preparation, review, and approval of the manuscript; and the decision to submit the manuscript for publication, along with their co-authors. The study sponsor approved the manuscript from an intellectual property perspective but had no right to veto the publication.
: Rahul Bhambri, A. Carmine Colavecchia, Marianna Bruno, Yong Chen, Jose Alvir, Anuja Roy, and Jason Kemner are employees of Pfizer and own stock/stock options. Aaron Crowley and Darrin Benjumea are employees of Genesis Research, LLC, which was contracted and paid by Pfizer for participation in this study. Lauren Gilstrap has no relevant disclosures.
: This study was conducted in accordance with the Code of Ethics of the World Medical Association (the Declaration of Helsinki).
: This study was based on de-identified data from Optum’s longitudinal EHR. No additional consent was required to conduct or publish this analysis.
: Upon request, and subject to review, Pfizer will provide the data that support the findings of this study. Subject to certain criteria, conditions and exceptions, Pfizer may also provide access to the related individual anonymized participant data. See ExternalRef removed for more information.
: Comorbidity diagnostic codes are provided in the Supplementary Material.
: RB, ACC, MB, YC, JA, AR, JK, AC, and DB contributed to the study conceptualization, data curation, formal analysis, investigation, methodology, project administration, validation, visualization, and writing – review and editing. RB, ACC, MB, YC, JA, AR, and JK additionally contributed to the funding acquisition and resourcing. LG contributed to the formal analysis, investigation, validation, visualization, and writing – review and editing.